SEC filing summary
Filing identity: The supplied filing is Leap Therapeutics, Inc.’s Form 10-Q, not a filing for Cypherpunk Technologies Inc. It covers the quarter ended June 30, 2021, and was signed August 13, 2021. Dollar amounts below are in U.S. dollars.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead candidate, DKN-01, is investigational and not FDA-approved. The filing reports second-quarter and first-half 2021 results, compared with the same 2020 periods. The company has no approved products or product sales; reported revenue is from its BeiGene agreement.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| License revenue | $0.375 million | $0.375 million | $0.750 million | $0.750 million |
| Research and development expense | $7.206 million | $5.350 million | $14.013 million | $9.953 million |
| General and administrative expense | $2.795 million | $2.521 million | $5.535 million | $4.674 million |
| Net loss | $9.526 million | $6.516 million | $18.660 million | $13.747 million |
| Net loss per share, basic and diluted | $0.12 | $0.12 | $0.24 | $0.57 |
| Operating cash used | Not presented quarterly | Not presented quarterly | $16.339 million | $13.377 million |
At June 30, 2021, cash and cash equivalents were $35.734 million, versus $52.071 million at December 31, 2020. Current assets were $36.020 million and current liabilities $8.056 million. Total liabilities were $8.056 million, primarily accounts payable, accrued expenses, deferred revenue and lease liabilities; the filing reports no borrowings. Stockholders’ equity was $29.884 million. No meaningful product gross margin is reported because the company has no product sales.
Material changes versus prior comparable periods
- Q2 operating expenses rose $2.130 million year over year; the net loss increased $3.010 million.
- First-half operating expenses rose $4.921 million and net loss increased $4.913 million year over year. R&D spending increased by $4.060 million, driven mainly by DKN-01 clinical development, staffing, manufacturing campaigns and trial costs.
- First-half cash used in operations increased to $16.339 million from $13.377 million. Cash declined by $16.337 million in the first half of 2021; the comparable 2020 period included $74.382 million of financing proceeds, largely from equity offerings.
- Australian R&D incentive income was $0.315 million in the first half of 2021, compared with $0.115 million in 2020. Foreign currency results were a $0.150 million loss in 2021 versus a $0.048 million loss in 2020.
Outlook, risks and notable items
- Management expects continued operating losses and increased R&D spending as DKN-01 development continues. It believes June 30 cash will fund operating expenses for at least 12 months from issuance of the financial statements, while also stating it will seek additional financing or collaboration support.
- Without additional funding or cost-sharing, Leap may need to delay, reduce or eliminate clinical trials and research programs or cut discretionary spending.
- Leap reported completion of enrollment in the 25-patient first-line cohort of the DisTinGuish Phase 2a gastric/GEJ cancer study of DKN-01 with tislelizumab and chemotherapy. Initial data were planned for presentation at ESMO in September 2021. The filing provides no clinical results from that cohort.
- The BeiGene agreement covers DKN-01 development and commercialization in Asia excluding Japan, Australia and New Zealand. Leap recognized $0.750 million of the original $3.0 million upfront payment in the first half; $0.750 million remained deferred at June 30. Leap may receive up to $132 million in future option and milestone payments, plus royalties, subject to terms and achievements; no royalties had been recognized.
- There were $2.0 million of noncancelable DKN-01 manufacturing commitments. European patent opposition proceedings concerning TRX518 patents remained pending; the filing reports no accrued liability for these matters. Management said there were no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the issuer identity: this document is Leap Therapeutics, Inc. (Nasdaq: LPTX), despite the request naming Cypherpunk Technologies Inc.
- Review cash runway assumptions, projected spending and the timing and availability of potential financing or collaboration funding.
- Verify the DisTinGuish study data, subsequent clinical milestones and whether any trial timing or enrollment has changed.
- Assess the BeiGene option status and the conditions, timing and likelihood of any future milestone or royalty revenue.
- Reconcile the 59.672 million issued and outstanding shares on the balance sheet with the higher weighted-average share count: the filing includes 16.718 million pre-funded warrant shares as outstanding for loss-per-share calculations. Also consider the substantial additional potential dilution from options, RSUs and warrants.